42 results about "Joint synovium" patented technology

A method of determining the voltage and current required for the application of specific and selective electric and electromagnetic signals to diseased articular cartilage in the treatment of osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies (cell transplantation, tissue-engineered scaffold, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient's hip. Anatomic, analytical, and planar circuit models are developed to determining the impedances, conductivities, and current flows in the human hip joint and its surrounding soft tissues and skin that are required to produce a 20 mV / cm electric field in the synovium and articular cartilage of the human hip. The voltage of the signal applied to the surface electrodes or to a coil(s) or solenoid is varied based on the size of the hip joint; larger hip joints require larger voltages to generate the effective electric field.

A mark substance of specificity - anti-genicity for atrophic arthritis is carbamyl ornithine fibre connexin existied in blood plasma and joint synovium tissue of atrophic arthritis patient. The invented mark substance has excellent application value in preparing reagent and medicine for diagnosing and curing disease of atrophic arthritis.

The invention discloses a bifidobacterium breve strain capable of relieving rheumatoid arthritis, and application of the bifidobacterium breve strain, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium breve strain CCFM1078 is screened out; the bifidobacterium breve strain CCFM1078 has the effect of relieving rheumatoid arthritis and is specifically embodied in that: RAW264.7 cells are remarkably promoted to secrete an anti-inflammatory factor IL-10; the joint thickness, clinical score and morbidity of a rat suffering from rheumatoid arthritisare remarkably reduced; the content of pro-inflammatory cytokines TNF alpha and IL-1 beta in serum of the rat suffering from rheumatoid arthritis is remarkably reduced; the content of short-chain fatty acid in excrement of the rat suffering from rheumatoid arthritis is remarkably adjusted; the proportion of Th17 cells in mesenteric lymph nodes of the rat suffering from rheumatoid arthritis is remarkably reduced; and, a pro-inflammatory factor IL-6 secreted by synovial cells is remarkably reduced.

The invention discloses a strain of Bifidobacterium breve that can relieve rheumatoid arthritis and its application, belonging to the technical field of microorganisms. The invention screened out a strain of Bifidobacterium breve CCFM1078, and the Bifidobacterium breve CCFM1078 has the effect of relieving rheumatoid arthritis, which is embodied in: significantly promoting the secretion of anti-inflammatory factor IL-10 by RAW264.7 cells; Joint thickness, clinical score, and morbidity in rheumatoid arthritis rats; significantly reduced serum pro-inflammatory cytokines TNFα and IL-1β in rheumatoid arthritis rats; significantly modulated feces in rheumatoid arthritis rats The content of short-chain fatty acids; significantly reduce the proportion of Th17 cells in the mesenteric lymph nodes of rheumatoid arthritis rats; significantly reduce the secretion of the pro-inflammatory factor IL-6 by synovial cells.

The invention discloses a preparation method and application of a noninvasive dermal penetration technology transdermal absorbent containing traditional Chinese medicine effective components. The transdermal absorbent comprises the following active ingredients: cortex dictamni, lumbricus, semen strychni and flos daturae extracts, an absorption transdermal patch is prepared, and the transdermal patch is stored through hair follicles. The traditional Chinese medicine transdermal absorbent has the advantages of avoiding the first-pass effect, inactivating gastrointestinal tracts, reducing the individual difference of medication and the like of a common transdermal preparation, also can achieve a long-acting slow release effect, and can maintain constant drug effect blood concentration and physiological effect within a certain time, and the cortex dictamni, the earthworm, the semen strychni and the flos daturae extract have anti-inflammatory and analgesic effects. The joint synovial tissue hyperplasia can be relieved, and the effects can be achieved in multiple aspects to treat arthritis.

Methods and surgical tools for treating back pain use a spinal facet joint debridement tool with a cautery and denudation action and a minimally invasive protocol that denies and cauterizes the soft tissue associated with the synovial bursa of the spinal facet joints.

The invention relates to a BPNs / chitosan / PRP temperature-sensitive hydrogel and a preparation method and application thereof. The present invention mainly mixes BPNs, chitosan thermosensitive hydrogel and activated PRP to prepare BPNs / chitosan / PRP thermosensitive hydrogel, through phototherapy of BPNs, biotherapy treatment of platelet-rich plasma (PRP) and phosphorus-driven Calcium extracts biomineralization for proliferation, so that it has good PTT and PDT effects, low cytotoxicity in different cells, and a survival rate higher than 85%; good biocompatibility, cell affinity and proliferation ability; in near-infrared light It is easy to generate ROS under irradiation, and reaches the maximum within 8 minutes, which can promote cell adhesion, growth and extracellular matrix generation; it can effectively remove hyperplastic synovial tissue, repair defective bone tissue and maintain the smoothness of the articular surface, and can be used as a photothermal and / or photodynamic drugs for the treatment of rheumatoid arthritis.

The invention encompasses compositions and methods for effectively treating and / or preventing the development and / or progression of osteoarthritis and rheumatoid arthritis and for promoting overall joint health. This is accomplished by totally addressing the key multiple biochemical processes and mechanisms that lead to such disorders. The invention includes compositions comprising a combination of natural agents that safely and effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that increase the risk for or lead to the development and / or progression of OA and RA. The present compositions are holistically formulated to be effective in preventing / arresting loss of and / or damage to the articular cartilage (AC) by suppressing (a) extracellular matrix (ECM) degradation, (b) chondrocyte apoptosis, and (c) inflammation of synovium through modulation of mechanisms that involve transcription factors, growth factors, kinases, antiapoptotic / apoptotic factors and deacetylases. The active agents used herein are natural materials, in particular phytonutrients (or phytochemicals), minerals and / or vitamins.

The invention provides an application of streptococcus salivarius K12 in preparing a medicament for preventing and / or treating autoimmune diseases, and belongs to the technical field of treatment of autoimmune diseases. Preventive intervention of the streptococcus salivarius K12 can inhibit occurrence and development of experimental arthritis, so that the incidence of the experimental arthritis isreduced by 30-70% and the synovial tissue of a joint can be prevented from infiltration and erosion of inflammatory cells; in addition, streptococcus salivarius also has therapeutic effects on the experimental arthritis. The streptococcus salivarius K12 can significantly down-regulate the ratio of Tfh cells, GCB cells, DC cells and Neu cells, inhibit the expression of proinflammatory cytokine IL-6, and promote the secretion of anti-inflammatory cytokine IL-10. The streptococcus salivarius can promote the immune steady-state reconstruction by inhibiting the immune response and provides a potential target for the treatment of rheumatoid arthritis; can target and regulate abnormal immune cells, treat diseases from an upstream way, and regulate immune balance.

The invention provides a composition containing licorice and other medicinal and food homologous Chinese medicinal ingredients (named Gancao Yangyin Decoction) and its application in rheumatoid arthritis and ovarian cancer. In parts by weight, the traditional Chinese medicine composition of Gancao Yangyin Decoction includes the following components: 2 to 6 parts of licorice, 1 to 5 parts of ginseng, 1 to 3 parts of dried ginger, 1 to 3 parts of dandelion, 2 to 6 parts of Luo Han Guo, jade 1 to 5 parts of bamboo, 2 to 6 parts of jujube. The traditional Chinese medicine composition provided by the invention adopts licorice as the monarch drug, ginseng and Polygonatum odoratum as the minister drug, dandelion, dried ginger and Luo Han Guo as the adjuvant drug, and jujube as the envoy drug. Moisturizes the lungs and relieves coughs, promotes body fluids and quenches thirst, nourishes yin and supports yang, and regulates the heart, lung, spleen and large intestine meridians. In vitro studies have confirmed that the drug serum of this formula inhibits the proliferative activity of rheumatoid arthritis synovial fibroblasts and ovarian cancer cells, and promotes their apoptosis. It has potential development value in the treatment of rheumatoid arthritis and ovarian cancer.

The invention relates to a monoclonal antibody capable of neutralizing CYR61 and applications thereof and a hybrid tumor capable of generating the monoclonal antibody. The technical scheme adopted by the invention relates to the monoclonal antibody secreted by the mouse anti-human CYR61 monoclonal antibody hybrid tumor CGMCC No.2766 or CGMCC No.2767, and the applications of the monoclonal antibody to preparation of a medicament for treating rheumatic disease, wherein the rheumatic disease is the chronic infectious arthritis. The invention has the advantages that: (1) the self-prepared monoclonal antibody can research pathogenesis of CYR61 in rheumatoid arthritis and can accurately position the expression of CYR61 and detect the CYR61 level of the blood serum and the lesion sites (such as joints); (2) the monoclonal antibody can be used for preparing a detection kit so as to distinguish clinical diagnostics of osteoarthritis and rheumatoid arthritis; and (3) the monoclonal antibody also can search the combination epitope where the CYR61 on the surface of the synovium and in the synovial of the rheumatoid arthritis patient can be neutralized, and provides the screening basis for preparing a humanized antibody which can neutralize the CYR61 in the next step.

The invention provides a quality control method and a quality control standard for the biological activity of osteopeptide for injection on rheumatoid arthritis, and relates to the field of drug quality control. It includes: using the MTT method to detect the inhibitory activity of osteopeptide for injection on synovial fibroblasts of rheumatoid arthritis; using the CCK-8 method to detect the inhibitory activity of osteopeptide for injection on monocyte-macrophages; and the dose-response The parallel line method was used to evaluate the biological potency and credible limit rate of osteopeptide for injection on rheumatoid arthritis synovial fibroblasts and monocyte-macrophages. The method has high repeatability, simple operation, rapid and accurate detection, which not only supplements the quality control method of osteopeptide for injection, but also can reflect the biological effect and quality of the drug more intuitively. The quality control standard of osteopeptide for injection formed by this method will help to ensure the safety, effectiveness and quality controllability of the drug more comprehensively and comprehensively.

The invneiton provides a cadinane sesquiterpene compound, and a preparation method and application thereof. The preparation method comprises the following steps: (1) preparation of fissistigma oldhamii extract: carrying out cold leaching or hot extracting on dried stem of the fissistigma oldhamii by using ethanol of which the volume concentration is 30 to 95 percent, thus obtaining an extracting solution; carrying out vacuum concentration, thus obtaining paste, i.e., the fissistigma oldhamii extract; (2) separation and purification: diluting the fissistigma oldhamii extract by using water to prepare a suspension solution, sequentially extracting by using petroleum ether and ethyl acetate, forming extractum by carrying out vacuum concentration on an ethyl acetate extracting solution, and carrying out column chromatography, thin layer chromatography, molecular sieve chromatographic separation and high-performance liquid-phase separation, thus obtaining the cadinane sesquiterpene compound. The invention also discloses the preparation method of the cadinane sesquiterpene compound and the application of the cadinane sesquiterpene compound in preparing medicine for resisting rheumatoid arthritis. According to the cadinane sesquiterpene compound disclosed by the invention, the activity of the cadinane sesquiterpene compound in inhibiting synovial cell proliferation of the rheumatoid arthritis is firstly discovered, and the cadinane sesquiterpene compound can be used for preparing the medicine for resisting the rheumatoid arthritis.

The present invention provides N 6 Use of -(2-hydroxyethyl)adenosine in the treatment of gout. Cordyceps Extract N 6 ‑(2‑hydroxyethyl)adenosine has a good analgesic effect by activating adenosine A1 receptors. By giving gout rats N 6 ‑(2‑hydroxyethyl), 932 genes were differentially expressed in the joint synovium, of which 57 were pain-related genes and 12 were analgesia-related genes. N 6 ‑(2‑Hydroxyethyl)adenosine significantly reduced joint swelling, levels of interleukin 1β (IL‑1β) and tumor necrosis factor alpha (TNF‑α) in serum and joint washing fluid, and decreased NLRP3 inflammasome , the level of caspase-1 (caspase-1), and promote autophagy and p62 degradation, play an anti-inflammatory and analgesic effect. Can be used to relieve pain and inflammation caused by gout.

A traditional Chinese medicine preparation is used as a new medicine for treating osteoarthritis. The clinical symptoms of osteoarthritis are: degeneration and destruction of articular cartilage, subchondral bone sclerosis or cystic degeneration, bone hyperplasia at the joint edge, synovial hyperplasia, Joint capsule contracture, ligament laxity or contracture, muscle atrophy and weakness, etc.; the traditional Chinese medicine preparation is made of the following raw materials in parts by weight: 700-1100 parts of red fish eye, 700-1100 parts of nine-layer wind, 450-800 parts of Ivy clover , 450-800 parts of Shanfeng, 160-320 parts of Liangmianzhen, 25-40 parts of Panax notoginseng stems and leaves, among which Shanfeng can also be replaced by an equal amount of Dafeng AI. The present invention uses the medicine originally used for treating rheumatoid arthritis, frozen shoulder and rheumatoid arthritis to treat osteoarthritis, and has remarkable curative effect in treating osteoarthritis, expands the indications of the original medicine, and provides a clinical A new drug for the prevention and treatment of osteoarthritis.